Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Assets (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Current Assets data on record, last reported at $21.3 million in Q1 2025.

  • For Q1 2025, Current Assets rose 49.62% year-over-year to $21.3 million; the TTM value through Mar 2025 reached $21.3 million, up 49.62%, while the annual FY2025 figure was $21.3 million, 49.62% up from the prior year.
  • Current Assets reached $21.3 million in Q1 2025 per SXTC's latest filing, up from $14.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $23.2 million in Q1 2021 and bottomed at $14.2 million in Q1 2024.
  • Average Current Assets over 5 years is $20.1 million, with a median of $21.3 million recorded in 2025.
  • Peak YoY movement for Current Assets: dropped 27.09% in 2024, then surged 49.62% in 2025.
  • A 5-year view of Current Assets shows it stood at $23.2 million in 2021, then dropped by 3.36% to $22.5 million in 2022, then fell by 13.05% to $19.5 million in 2023, then decreased by 27.09% to $14.2 million in 2024, then soared by 49.62% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $21.3 million in Q1 2025, $14.2 million in Q1 2024, and $19.5 million in Q1 2023.